ATTO — Attovia Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $661.94m
- $546.81m
- $1.35m
Annual income statement for Attovia Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A |
| Standards: | USG | USG |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 0 | 1.35 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Total Operating Expenses | 41.6 | 68.5 |
| Operating Profit | -41.6 | -67.2 |
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -39.8 | -60.6 |
| Net Income After Taxes | -39.8 | -60.6 |
| Net Income Before Extraordinary Items | ||
| Net Income | -39.8 | -60.6 |
| Adjustments to Net Income | ||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -45 | -60.9 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -1.05 | -1.42 |
| Dividends per Share |